1. Recombination frequencies of human leukocyte antigen loci in hematological malignancies among Turkish population.
- Author
-
Kekik, Cigdem, Temurhan, Sonay, Ogret, Yeliz, Akgul, Sebahat Usta, Hayriye Senturk, Ciftci, Besisik, Sevgi Kalayoglu, and Oguz, Fatma Savran
- Subjects
HLA-B27 antigen ,BONE marrow transplantation ,GENETICS ,RETROSPECTIVE studies ,HEMATOLOGIC malignancies ,DESCRIPTIVE statistics ,GENETIC techniques ,ETHNIC groups ,HEMATOPOIETIC stem cell transplantation ,GENEALOGY ,TRANSPLANTATION of organs, tissues, etc. - Abstract
Introduction: Allogeneic hematopoietic stem cell transplantation (HSCT) is a treatment option with growing performance for leukaemia, aplastic anaemia and genetic disorders. The frequency of MHC (Major Histocompatibility Complex) gene locus recombination is increased at loci close to the telomeres and in the female gender. The aim of the present study is to document the recombination events by pedigree diagrams with the primary goal to determine the frequency of recombination in a different ethnic population from mostly reported studies. Methods: Altogether 9545 allogeneic HSCT recipients and their family‐based potential donors (n:36231) were included in this retrospective study. Results: Recombinations were determined in 118 (F/M:50/68) out of 9545 families enrolled on the study. These were present in 40 of the patients and 78 of healthy donors. The frequency of recombinations was 0.42% and 0.22%, in patients and donors, respectively. Of the 118 recombinations, 60 were detected in A locus (13 inpatients), 14 in B locus (3 inpatients) and 42 in DR locus (22 inpatients). In our study, due to recombinations in HLA (Human Leukocyte Antigen)‐A,‐B,–DR loci, we found that some patient‐donor pairs became 6/5 matched instead of 6/6 (n:45), eliminating the allogeneic HSCT possibility for the patients from the full‐matched siblings. Conclusion: To our knowledge, this is the first study reporting the recombination frequencies in HLA loci among Turkish population and thus, providing informative data to the clinicians regarding the cross‐over possibilities in Turkish patients with haematological malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF